RESULTS MATTER 2 013 A N N U A L R E P O RT Allergan is a company that consistently delivers solid results. Financially, we have achieved mid-teens sales growth on a compounded annual basis over the past 15 years, with strong year-over-year earnings growth as well. Commercially, we have benefited from a broad and balanced portfolio of products that are market leaders in several important and growing categories. And scientifically, we continue to deliver on our promising pipeline. These are significant results, and they matter. They demonstrate Allergan’s winning formula for achieving consistent growth despite a challenging business and health care environment. They illustrate the value of rooting our success in strong and durable relationships with our customers. And they point to a promising future. Results matter to the many people who have a stake in Allergan – our customers, patients, investors, employees and partners. That is why we will stay focused on delivering strong results: day after day, quarter after quarter, year after year. Table of Contents Letter To Our Investors Eye Care Facial Aesthetics Pipeline Emerging Markets 2013 Accolades 1 6 8 10 12 14 Financial Summary Reconciliation of Non-GAAP Adjustments Board of Directors Executive Committee Corporate Overview and Stockholders’ Information 16 18 20 22 24 To Our Investors RESULTS THAT MATTER In 2013, we were once again able to deliver strong results, in line with our long term aspirations of growing revenues in local currencies in excess of 10% per annum and growing adjusted Earnings per Share around the mid teens. In fact, we reported strong 12.4% revenue growth in local currencies and 11.7% growth in U.S. Dollars. Adjusted non-GAAP Diluted Earnings per Share increased 18.1% in 2013 over 2012, after we continued to invest into the long term drivers of success, namely Research & Development (R&D), where we increased our investment to $1,034.7 million, an increase of 13.1%, all on a non-GAAP basis.1 We were encouraged by the acceleration of revenue growth in the second half of the year as the company benefited from many product approvals since 2010 from the U.S. Food & Drug Administration (FDA) and the commensurate regulatory agencies around the world; and furthermore, from a strengthening of many major economies, buoyant market conditions, as well as from market share gains in most of our product categories. In general, we observed weakening competition from the principal players in our markets, as they adjusted to imperatives under new ownership, focused on improving short term financial performance or made cutbacks after losing patent exclusivities. In ophthalmology, Merck & Co, a key competitor for decades, announced their exit by divesting their products in the U.S. to another company. Our operating performance throughout 2013 was strong. In fact, this performance got progressively stronger during the year driven by a broad array of products across virtually all of our regions. We reported a record adjusted non-GAAP gross margin at 87.3%, an increase of 80 basis points from 2012, as we benefited from decreased royalty payments to third parties and a decrease in the manufacturing cost of goods by 0.3%, as a percentage of product net sales. In fact, as a testament to our long term investment in R&D and the creation of intellectual property, for the first time in 2013 our royalty payments were exceeded by royalties received, principally from Senju and GlaxoSmithKline in Japan and from Alcon regarding our out-license of certain brimonidine glaucoma technology. Reduction in cost of goods was the result of leveraging the small number of highly capitalized pharmaceutical and medical plants in our global network with rising volumes, high capacity utilization and targeted investments in automation and efficiency. In addition, we generated a record of just over $1.5 billion in free cash flow, which has provided us considerable balance sheet strength for making potential acquisitions and in-licensing technology to further drive the prospects for long term growth of the company. In the last 15 months we acquired SkinMedica for approximately $350 million and MAP Pharmaceuticals (MAP) for approximately $870 million. The SkinMedica acquisition brought us the leading position in the fast growing U.S. physician dispensed category 2 and an ability to expand our already very broad offering of medical aesthetics products; the MAP acquisition brought us LEVADEX®, a self-administered breath activated orally inhaled dihydroergotamine product, currently under review by the FDA, for the acute treatment of migraine. This is a complementary product to BOTOX® (onabotulinumtoxinA) for chronic migraine. Whilst the product indications are distinct, there is a considerable overlap in the physician groups treating migraine patients. Given the pressures facing the worldwide pharmaceutical and medical device industries, we are pleased with the earnings results achieved after absorbing considerable mandated taxes and fees. As our contribution to the costs of healthcare reform in the U.S., Allergan paid approximately $130 million to the U.S. Government in terms of increased rebates, fees and taxes including the Medical Device tax, an increase of approximately $30 million from 2012. 1 2 The adjusted amounts represent certain non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to GAAP financial measures, please refer to pages 18 and 19 of this Annual Report. Physician-Dispensed Topicals: Ongoing Product Innovation, Medical Insight, Inc., July 2013 Worldwide Sales – Broad and Balanced Portfolio FY 2013 – $6.2 Billion 1 (+12%)* Global Reach Balanced Revenue Growth Across All Operating Regions (in billions of dollars) ~62% Reimbursed vs. ~38% Cash Pay 4 YR CAGR $6.2* Ophthalmics 47% +10% North America Europe, Africa & Middle East Asia Pacific Latin America (Reimbursed 39%, Cash 8%) $5.5* BOTOX® Therapeutic 17% $5.1* (Reimbursed 17%) $4.6* $4.2* +9% BOTOX® Cosmetic 15% (Cash 15%) Facial Aesthetics 8% (Cash 8%) +11% Breast Aesthetics 6% (Reimbursed 1%, Cash 5%) LATISSE® 2% +19% (Cash 2%) +11% Skin Care 5% (Reimbursed 5%) 1 Excludes Obesity Intervention product net sales * Growth in Local Currency 09 10 11 12 * Excludes Obesity Intervention product net sales in all periods 13 1 SOME CHALLENGES IN 2013 Of course, the year was not without some challenges. As a company focused on delivering long term revenue growth, we regularly and objectively review where we should focus our financial and managerial resources. In spite of the clear need to address obesity worldwide, sales of our obesity intervention products were recently in decline, principally due to patients experiencing barriers to access in terms of coverage by their healthcare plans, to patient co-pays and, in addition, to recent surgeon adoption of an alternative bariatric procedure. Having declared the LAP-BAND® System and ORBERA® gastric balloon, the latter sold outside the United States, as a discontinued business in early 2013, we were pleased that we were able to divest this product line in December to Apollo Endosurgery. This divestiture will enable us to concentrate our management resources on the many growth products in our businesses. Strategically, we have no interest in maintaining product lines with declining sales growth in our portfolio. Although we have been highly successful in securing product approvals, with no less than 11 such FDA approvals since the beginning of 2010, the R&D process in pharmaceuticals and medical devices abounds with technical and scientific challenges. We experienced some of these, resulting in delays in 2013. Regarding LEVADEX®, which we had acquired from MAP, we received input from the FDA regarding the manufacturing process and required additional data from additional production lots. In order to fully satisfy the FDA’s demands and to control quality standards, we acquired MAP’s third-party canister filling supplier in early 2013. Our response to the FDA’s complete response letter was filed in December 2013 and we expect to receive FDA approval for the product in the second quarter of 2014. Subsequent to our in-license of DARPin® technology, for the treatment of macular degeneration, from Molecular Partners in Zurich in 2012, we conducted our initial clinical trial that could have provided data to allow us to advance directly into phase 3 trials, demonstrate longer duration compared to existing products, and allow us to decrease overall development time. Unfortunately, we did not have the results to support going directly into phase 3 and decided to adopt a new clinical protocol that is similar to those used by earlier competitive products, which has led to a one to two year delay in the program. We remain excited, however, by the promise of this technology to bring a differentiated, superior product to market to lessen the burden of this disease for patients. Finally, investors experienced some concerns regarding Allergan’s ability to defend its patents regarding RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for therapeutic chronic dry eye and LUMIGAN® 0.01% for glaucoma. In early 2014, a U.S. District Court in Texas ruled that all five of the LUMIGAN® 0.01% patents in suit are valid and infringed, and enjoined the generics from launching their products until the patents expire, the last of which expires in 2027. Several generic companies have filed appeals to the U.S. Court of Appeals but would need to convince the Court to invalidate or find non-infringement of all five patents to be successful. Regarding RESTASIS®, we believe it will remain the only product approved by FDA and several regulatory agencies abroad for therapeutic chronic dry eye for some length of time. The clinical requirements were onerous for Allergan and we too did not receive approval upon our first Ability to Leverage SG&A Non-GAAP SG&A as a Percentage of Sales1 1 18% 09 10 11 12 13 09 10 11 39.1 14% 39.2 12% 40.0 14% 40.5 8% 41.1 $ 4.04 $ 3.55 $ 3.16 $ 4.77 Mid Teens EPS Growth Aspiration Non-GAAP Diluted Earnings Per Share1 $ 2.78 2 Regarding bimatoprost scalp, the same active pharmaceutical ingredient (API) in LATISSE® (bimatoprost ophthalmic solution) 0.03%, approved for the growth of eyelashes, the results of our phase 2 trial for male and female scalp hair loss were insufficient to proceed to phase 3. As the formulation was well tolerated, a decision was made to conduct an additional phase 2 trial with a higher concentration of API from the previous phase 2. Male patients with androgenic alopecia have been enrolling in this trial, and we expect the trial to complete by mid-year 2015. 12 13 The adjusted amounts represent certain non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to GAAP financial measures, please refer to pages 18 and 19 of this Annual Report. 2009 and 2010 include the obesity intervention business. David E.I. Pyott, CBE, Chairman of the Board & Chief Executive Officer 3 submission to FDA. Several other programs from other companies have suffered similar issues. Given the value of RESTASIS® with sales approaching $1 billion in the U.S. alone, it is not so surprising that the Office of Generics Drugs at FDA issued a draft guidance for public comment on how generic companies could present a clinical package to secure approval for a generic of RESTASIS®. Given earlier comments by officials both in the Review Division, the group responsible for approving new drugs, as well as by others in the Generics Division, it was however surprising that this Draft Guidance established a pathway based solely on in vitro assays. In addition to Allergan, 22 medical societies, patient groups and consumer groups submitted comments, all raising concerns about public health and safety if generics were to be approved of our complex “oil in water” emulsion formulation. Given the key importance of our formulation, method of use and manufacturing process in ophthalmic pharmaceuticals, Allergan was able to secure four new patents, originally filed in the early 2000’s at the U.S. Patent Office, and listed in the Orange Book in January and February 2014. We have also filed a Citizen’s Petition with the Generics Division of the FDA. All of this provides us several legal avenues to vigorously defend RESTASIS®. Whilst Watson Pharmaceuticals (Actavis) notified us that they submitted a generic RESTASIS® filing with FDA, they also admitted the agency refused to receive that submission for filing. The status of any generic filings is currently unclear but the situation may become more clear by the middle of 2014, and we are confident that we have taken all of the appropriate steps to protect our therapeutic dry eye franchise. POWER AND SUSTAINABILITY OF GROWING MARKETS Notwithstanding these challenges, Allergan remains in an extremely strong and enviable position. We are the No. 1 or No. 2 player in each of our therapeutic areas with our markets enjoying strong growth and continuing growth potential 3 as we address the therapeutic needs of an aging world population that, aesthetically, would also like to maintain a youthful appearance. These market positions, combined with our presence in all continents of the world and considerable investment in R&D, makes us an ideal partner or natural purchaser for companies with technology assets in our fields. Our long term track record has demonstrated our ability to not only invent products internally, but also to shepherd externally acquired technologies through the processes of clinical development, approval by regulatory agencies and to successful reimbursement and adoption in the marketplace. BALANCED GROWTH ACROSS SPECIALTIES AND GEOGRAPHIES A strong company built to last demonstrates strong growth across countries as well as product lines, and this was the case for Allergan in 2013. Most of our operating regions, namely North America pharmaceuticals; the U.S. Medical Aesthetics business unit; 3 Mixture of public information (earnings releases, earnings calls, 10Ks, 10Qs), AGN internal data, syndicated marketing research reports, analyst reports, Internet searches, competitive intelligence, market trackers, etc. for U.S. Dollar sales at actual rates for four quarters ending September 2013. Europe, Africa, and Middle East; and Asia Pacific, all enjoyed double digit sales growth in local currencies. The only exception was Latin America, where we made the strategic decision to lower inventories of breast aesthetics products in Mexico and Columbia in advance of terminating our distributor arrangements and going direct in January 2014, and we were additionally held back by the lack of foreign exchange for imports in Venezuela. BOTOX® sales continued their trajectory of double digit growth in 2013, increasing by 13.2% in local currencies and 12.2% in U.S. Dollars to almost $2 billion. With recent approvals by FDA and many global regulatory agencies, for chronic migraine and two urological conditions: neurogenic overactive, or spastic bladder and idiopathic overactive bladder, or severe incontinence, therapeutic sales of BOTOX® further accelerated, growing 16% in local currencies. In the U.S., BOTOX® now has eight approved therapeutic indications along with the well-known aesthetic indications for BOTOX® Cosmetic (onabotulinumtoxinA) for moderate to severe glabellar lines and a newly approved indication for moderate to severe lateral canthal lines, or crow’s feet lines. Worldwide, BOTOX® enjoys more than 27 different approved indications across approximately 88 countries. Aesthetic global sales accounted for approximately 46% of BOTOX® global sales and increased by 10% in local currencies. Our other consumer-facing franchises also performed well in 2013, even in economically challenged markets such as in Southern Europe. Dermal fillers sales were propelled by the introduction of the unique and technologically advanced VYCROSS® lines – made up of JUVÉDERM VOLUMA® XC to correct age-related volume loss in the cheek area, VOLBELLA® for lip augmentation, and VOLIFT® for nasolabial folds. FDA approved the first of these products, JUVÉDERM VOLUMA® XC at the end of 2013. Physicians and their patients appreciate the softness and duration of these products everywhere where they have been introduced, leading to an upswing in market growth and market share gains for Allergan. In breast aesthetics, sales growth at only 0.2% in U.S. Dollars was on the surface low but was affected by the one time surge in growth in Europe in 2012 as patients chose Allergan’s NATRELLE® high quality products for revision surgery upon explantation of silicone implants fraudulently produced by a French manufacturer. Sales were also negatively affected by the abovementioned drawdown of inventory in Mexico and Colombia and import restrictions into Venezuela. Offsetting this were initial shipments to Japan, where NATRELLE® is the only implant line approved, and major expansion in China. Within the skincare segment, ACZONE® (dapsone) gel 5%, responded to an investment in direct to consumer advertising as well as focused detailing to dermatologists, and is poised to become the largest acne brand in the U.S. by value.4 4 IMS IMS IMS 7 IMS 8 IMS 5 6 NPA TRx Pharmacy $ Dermatology Segment Full Year 2013 YTD Q3-2013 worldwide (53-country rollup) U.S.$ growth estimates at Q3-13 constant exchange rates (among top six companies) MAT Q3-2013 worldwide (53-country rollup) U.S.$ sales estimates at Q3-13 constant exchange rates 53-country rollup and selected OTC CE data YTD Q3-2013 sales @ AGN 13 Budget rates MAT Q3-2013 worldwide (53-country rollup) U.S.$ growth estimates at Q3-13 constant exchange rates (among top six companies) Leading Market Share Positions in Growing Markets Worldwide Market in Billions of Dollars With Aggregate Growth 2009-2013 09 $1.7 Q3 13 MAT 09 AGN #1 $1.2 Allergan Valeant/Medicis Merz Others $0.9 $0.8 Allergan Valeant/Medicis Merz/BioForm Others Allergan J&J/Mentor Others $0.7 AGN #2 AGN #1 Allergan Novartis/Alcon Pfizer Others Breast Aesthetics +13% AGN #2 $14.7 $2.7 AGN #1 AGN #2 $20.2 Fillers +71% AGN #1 Neuromodulators* +59% Ophthalmics +37% AGN #2 4 Representing almost half of our worldwide revenues, ophthalmic pharmaceuticals grew 8% in local currencies in 2013, with Allergan being the fastest growing global company, excluding retinal therapeutics.5 With growing appreciation by healthcare providers that therapeutic dry eye is a progressive disease and merits early treatment, RESTASIS® sales grew strong at 19% in local currencies, and RESTASIS® became the No. 1 eye drop worldwide and further consolidated its position as the No. 1 branded product by value in the U.S. market.6 In addition, Allergan’s artificial tears franchise as reported by IMS Global, grew 2%, with growth accelerating across the year as Allergan benefits from the introduction of OPTIVE® Advanced (marketed as OPTIVE PLUS™ in many overseas markets, as well as OPTIVE FUSION™ in Europe). The latter, a powerful combination of hyaluronic acid and carboxy methyl cellulose polymers, is Allergan’s first entry into the hyaluronic acid category, which accounts for nearly 30% of the overall market in Europe and about a 60% share in the Asia Pacific Region.7 In the glaucoma market, Allergan, per IMS Global, was the fastest growing global company,8 as we Q3 13 MAT 09 Q3 13 MAT 09 Q3 13 MAT Sources: Ophthalmics – IMS Global (53 countries) at Q3 2013 constant exchange rates. Neuromodulator/Filler/Breast/Banding – Mixture of public information (earnings releases, earnings calls, 10Ks, 10Qs), AGN internal data, syndicated marketing research reports, analyst reports, internet searches, competitive intelligence, market trackers, etc. * Neuromodulators include Therapeutic and Cosmetic benefited from a very broad product offering, for both first line and combination glaucoma treatments, with LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, GANFORT™ (which is not approved in the U.S.), ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and COMBIGAN® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%. Sales in Europe benefited from the introduction in 2013 in several markets of LUMIGAN® and GANFORT® unit dose, offering a preservative free alternative to ophthalmologists. In the U.S., physicians recognized the benefits of the newer LUMIGAN® 0.01% product offering the same efficacy as the first generation product, but with less hyperemia. Consequently, Allergan no longer markets LUMIGAN® 0.03% in the U.S.. In the retina segment, OZURDEX® (dexamethasone intravitreal implant), a steroid delivered in a bioerodable implant to the back of the eye and indicated for the relatively small indications of retinal vein occlusion and uveitis, grew strongly in Europe and the U.S.. We filed for approval of the larger indication of diabetic macular edema in both the U.S. and Europe in 2013 and anticipate approval in the U.S. in Q2 of 2014 and in early 2015 for Europe. PROMISING OUTLOOK As we address the challenges of 2013 and benefit from our strong diversified portfolio of products, we intend to continue to invest heavily in the future. We plan to increase our expenditure on R&D from $1 billion in 2013 to approximately $1.5 billion in the coming five years, focusing in particular on our key areas of new indications and new forms of botulinum toxin, retinal therapeutics, dry eye, glaucoma, medical and aesthetic dermatology and plastic surgery. In pursuing these goals, we constantly strive to adapt our business processes and gain new business efficiencies. To this end, we announced in early 2014 a modest restructuring program impacting approximately 300 associates worldwide, with a net reduction of 150 positions, and entailing a charge of between approximately $40 million and $45 million with less than a two year payback. In addition to reducing the size of our U.S. glaucoma sales force due to changing market conditions heavily influenced by the universe of payors, we also moved some back office operations from high cost California to Texas. In delivering the strong results for 2013, I wish to thank the management team and employees around the world for their attention to detail in executing our clearly defined corporate and product strategies. I wish also to acknowledge our strong Board of Directors, with their broad range of professional and geographical skill sets, in guiding the long term direction of Allergan. Sincerely, 5 David E.I. Pyott, CBE Chairman of the Board & Chief Executive Officer Major Product Approvals 1 2 PRODUCT INDICATION1 COUNTRY BOTOX® (onabotulinumtoxinA) Treatment of overactive bladder with symptoms of urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication United States and other global markets BOTOX® (onabotulinumtoxinA) Temporary treatment of moderate to severe lateral canthal lines, commonly known as “crow’s feet” lines United States and 19 countries of the European Union, Norway, Iceland2 JUVÉDERM VOLUMA® XC Dermal Filler Temporary correction of age-related volume loss in the cheek area in adults over the age of 21 United States NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants Women undergoing breast augmentation, revision or reconstructive surgery United States, Japan Specific indication verbiage varies by country. Approvals as of February 5, 2014. 6 A Proud History, A Promising Future: Allergan’s Leadership in Eye Care For more than 60 years Allergan has been a pioneer in innovative eye treatments. While other companies have entered and exited the field over this time, we have remained committed to developing and providing important products for serious eye conditions. Today we are the fastest growing ophthalmics company and the second largest in the world.1 And the solid results we have consistently delivered in this business have formed the foundation of Allergan’s success as a specialty- and patient-focused company. In 2013, prescription and over-the-counter eye care treatments accounted for nearly 50 percent of Allergan’s total global sales. Key product highlights for the year include: • • • RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, for chronic dry eye due to inflammation and the only prescription dry eye product in the U.S., reached nearly $1 billion in sales. In glaucoma, we obtained approval in the European Union (EU) for LUMIGAN® (bimatoprost ophthalmic solution) 0.01% unit dose and GANFORT® (bimatoprost timolol maleate) 0.01% unit dose, which provide important new treatment options to eye care professionals in the region. We filed with the U.S. Food and Drug Administration and with EU regulatory authorities for approval of OZURDEX® (dexamethasone intravitreal implant) to treat Diabetic Macular Edema, a serious eye disorder that is on the increase due to rising rates of type 2 diabetes. We anticipate U.S. approval of this important new indication this year and in early 2015 for Europe. “The Allergan story begins with strong science, leading to a steady stream of innovative new products that can make a real difference for many people,” says Julian Gangolli, Corporate Vice President and President of North America. “Innovation and partnership with the medical community have driven the success of Allergan’s eye care business and will continue doing so.” 1 Mixture of public information (earnings releases, earnings calls, 10Ks, 10Qs), AGN internal data, syndicated market research reports, analyst reports, internet searches, competitive intelligence, market trackers, etc. “The positive results we achieve in eye care will not only benefit patients but further strengthen our company’s leadership and future.” Doug Ingram, President of Allergan Worldwide RESTASIS® Sales $ 792 $ 697 $ 621 $ 523 $ 940 (in millions of dollars) OZURDEX® (dexamethasone intravitreal implant) is currently approved in the U.S. for macular edema following retinal vein occlusion and non-infectious ocular inflammation, or uveitis. 09 10 11 12 13 7 8 Driving Results Through Innovation in Facial Aesthetics In 2013, Allergan’s Facial Aesthetics business delivered strong results by innovating, adapting and staying close to the customer. Sales of BOTOX® Cosmetic (onabotulinumtoxinA) – already the number-one minimally invasive aesthetic medical treatment globally1 – are benefiting from its latest approved indication, to temporarily treat moderate to severe lateral canthal lines, commonly known as “crow’s feet” lines. We received U.S. Food and Drug Administration approval for this new indication in 2013, and also have secured national licenses in 19 countries of the European Union as well as Norway and Iceland. BOTOX® Cosmetic is the first and only product of its kind approved for this use. Allergan is also the world leader in dermal fillers.2 Global sales of Allergan’s JUVÉDERM® family of products, which address the mid and lower parts of the face, are growing robustly, thanks to market expansion and innovative products. These include the new line of products using Allergan’s proprietary VYCROSS® technology, which results in a smooth gel that flows easily and consistently. This unique formulation contributes to the lift capacity to correct volume loss. VYCROSS® technology is available in JUVÉDERM VOLUMA® XC for cheeks, VOLBELLA® for lips and VOLIFT® for nasolabial folds. Many of these products are available outside of the U.S. in markets such as Europe, Asia Pacific and Latin America. “The science behind these products, as well as the extensive education and training we undertake with our customers, translates into very strong results for this business,” says Simone Agra, Vice President, Medical Aesthetics, Latin America. In October 2013, JUVÉDERM VOLUMA® XC was approved in the U.S. as the first and only dermal filler for deep injection to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. “Gauging from the strong interest in these first few months on the market, we believe it will be an important transformative product in the U.S., just as it has been in many international markets,” says Philippe Schaison, President of Allergan Medical U.S. 1 2 Allergan data on file. Mixture of public information (earnings releases, earnings calls, 10Ks, 10Qs), AGN internal data, syndicated market research reports, analyst reports, internet searches, competitive intelligence, market trackers, etc. Our winning formula for achieving strong results is constantly innovating and listening closely to our customers. Worldwide Aesthetic Market Innovation Stimulates Both Market and Allergan Growth (in billions of dollars) $5.0* Neuromodulators Fillers Breast LATISSE® $3.2 $2.3 09 12 17 * Market projections based on Allergan estimates 9 10 Investing for Future Results: The Allergan Pipeline Allergan’s pipeline represents our long-term strategy of investing significantly in R&D while rigorously reviewing and culling our portfolio of candidates. By doing this – and through targeted acquisitions – we look to ensure a steady stream of new products across our five medical specialties: eye care, medical aesthetics, medical dermatology, neurology and urologics. “Results matter for Allergan’s R&D organization,” says Scott Whitcup, MD, Executive Vice President, R&D, and Chief Scientific Officer. “Generating, measuring and interpreting data drive the decisions regarding our research programs and lead to the approval of new therapies.” For an R&D organization, success is measured by product approvals. Dr. Whitcup adds: “New products are critical to our patients as well as to supporting overall company performance, allowing us to invest in R&D and constantly fuel the pipeline.” Our pipeline also includes important acquired and in-licensed products, such as DARPin®, for age-related macular degeneration, and LEVADEX®, a self-administered, orally inhaled and breath activated therapy for the acute treatment of migraines in adults. In addition, in January 2014 we completed a licensing agreement with Medytox, Inc., of South Korea, to develop and, if approved, commercialize certain neurotoxin product candidates currently in development, including a potential liquidinjectable product. Allergan’s R&D strategy concentrates on developing differentiated, commercially successful treatments. To that end, we employ an efficient R&D model – one focused on our specialties and yielding products that are localized in their impact and do not have a systemic effect in the body. This focused strategy and unique product development approach enables Allergan to bring products through the worldwide regulatory processes and onto the market at a rate above the industry average. In 2013, Allergan secured a record 180+ approvals for a variety of products and indications across the world. Significant R&D Investment Consistently Fueling the Pipeline Anticipated Near Term Product Approvals and Clinical Data LEVADEX® U.S. FDA expected approval – Q2 2014 $1,0351 $ 915 1 $ 826 1 $1,500 2 (in millions of dollars) OZURDEX® for Diabetic Macular Edema U.S. FDA expected approval – Q2 2014 BOTOX® (onabotulinumtoxinA) for Depression Entering Phase II – 2nd half of 2014 DARPin® Phase II Stage III data – 2nd half of 2014 1 2 11 12 13 17 The adjusted amounts represent certain non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to GAAP financial measures, please refer to pages 18 and 19 of this Annual Report. Allergan’s long-term goal Bimatoprost Sustained Release Glaucoma Phase II Data – late 2014 / early 2015 11 12 Maximizing Opportunities and Delivering Results in Emerging Markets Allergan sees great possibility in emerging markets, where rapidly growing economies and developing healthcare systems are opening exciting new business opportunities. For the past five years, we have undertaken a careful and measured strategy to maximize these opportunities in a way that draws on our unique strengths as a specialty company while also addressing unmet needs in those markets. “We look to enter markets where we can capitalize on the breadth of the Allergan portfolio, to meet surging demand for quality products across therapeutic areas,” says Doug Ingram, President of Allergan and former President of Europe, Africa and the Middle East. “We apply the same results-oriented discipline to our emerging markets strategy as we do to our approach to established markets.” Key emerging markets include Russia, where our eye care business has nearly tripled in revenue last year and where our Medical Aesthetics products are market leaders.1 China is another vitally important market for us, with BOTOX® Cosmetic and eye care products being the main drivers of growth. India, Turkey, South Africa and Brazil are just a few of the other emerging growth markets for Allergan. Japan, while clearly a mature economy with a highly developed health care system, is an emerging market for Allergan and currently our highest growth market. In 2013, sales were driven by BOTOX Vista® for aesthetic use. We also introduced our innovative NATRELLE ® 410 highly cohesive anatomically-shaped breast implants in that country. “The strong results we have been able to deliver in China, Japan and other emerging markets demonstrate the value of focusing on the unique opportunities in these regions,” says Ian Bell, President of Asia Pacific. “As traditional developed markets continue to face a wide variety of challenges, these regions will take on even greater importance for Allergan.” 1 Allergan data on file. Since 2009, Allergan has launched direct operations in South Korea, China, Poland, Turkey, Philippines, South Africa, Russia, Indonesia and Vietnam. 13 Emerging Markets Revenue Growth (in millions of dollars) $1,200 $1,000 $800 $600 $400 NATRELLE® 410 highly cohesive anatomically-shaped breast implants $200 are the first anatomically-shaped breast implants approved by local health authorities for reconstructive surgery in Japan. $0 +9% +26% +22% +17% +15% 09 10 11 12 13 Emerging Markets: Latin America, Asia (excluding Australia and New Zealand), EAME Emerging Markets. Growth in Local Currency Recognizing Our Results in Leadership and Social Responsibility E XECUTIVE MAN A GE M E N T For the second year in a row, Institutional Investor named Allergan one of its “Most Honored Companies” in the pharmaceutical sector, with David E.I. Pyott Best CEO and Allergan’s Investor Relations team Best Investor Relations, based on votes by sell side analysts. The National Law Journal recognized Allergan’s Legal team as the top legal department in Southern California. Phoenix House of California, the state’s leading non-profit substance abuse services organization, honored David E.I. Pyott for his business and philanthropic leadership. 14 The Marine Corps Scholarship Foundation honored David E.I. Pyott with the Semper Fidelis award. B USINES S Nielsen ratings named the RESTASIS® television ad one of the top 10 most memorable TV ads in the U.S. across all product categories. BOTOX® (onabotulinumtoxinA) for Chronic Migraine was a finalist for Best Biotechnology Product in the 2013 Prix Galien USA Awards, which recognize extraordinary achievements in biopharmaceutical research and development. Orange County Business Journal named Allergan one of the Best Places to Work. CIO magazine recognized Allergan as one of the top 100 companies for the exceptional use of Information Technology. C ORPORATE SOCIA L RE SPO N SIBIL ITY Allergan was one of just three pharmaceutical companies on the Dow Jones Sustainability Index for North America. 15 The U.S. Environmental Protection Agency’s Green Power Partnership named Allergan as one of its Top Partners for leadership in using green power to help reduce the impact of conventional electricity usage. For the second time in the past six years, the U.S. Environmental Protection Agency (EPA) named Allergan ENERGY STAR Partner of the Year for energy efficiency. And for the sixth year in a row, Allergan’s pharmaceutical plant in Waco, Texas, received the EPA ENERGY STAR certification for excellence in energy efficiency. For the sixth year in a row, the Brazilian pharmaceutical trade organization, Sindusfarma, cited Allergan’s manufacturing facility in Guarulhos, Brazil, for Excellence in Health and Safety Management. Financial Summary Y E A R E N D E D D E C E M B E R 3 1, In millions, except per share data 2013 2012 2011 2010 2009 S TAT E M E N T O F O P E R AT I O N S H I G H L I G H T S (as reported under U.S. GAAP) Product net sales Total revenues Research and development Earnings from continuing operations Earnings (loss) from discontinued operations Loss on sale of discontinued operations Net earnings attributable to noncontrolling interest Net earnings attributable to Allergan, Inc. Net basic earnings per share attributable to Allergan, Inc. stockholders: Continuing operations Discontinued operations Net diluted earnings per share attributable to Allergan, Inc. stockholders: Continuing operations Discontinued operations Dividends per share ADJUSTED AMOUNTS 16 $ 6,197.5 6,300.4 1,042.3 1,272.5 14.1 (297.9) 3.6 $ 985.1 $ 5,549.3 5,646.6 977.3 1,100.7 1.8 3.7 1,098.8 $ $ $ 4.28 (0.96) $ 3.64 - $ 3.11 (0.04) $ 4.20 (0.94) $ 3.57 0.01 $ 3.05 (0.04) $ 0.20 $ 0.20 $ $ 1,439.1 $ 1,240.6 $ 4.85 $ $ 4.77 $ 2,890.3 1,982.2 466.5 5,339.0 $ 5,144.0 5,216.0 871.5 949.6 (11.5) 3.6 934.5 $ $ 4,819.6 4,919.4 804.6 4.9 4.3 0.6 $ $ 4,447.6 4,503.6 706.0 623.8 2.5 621.3 - $ 2.05 - $ - $ 2.03 - 0.20 $ 0.20 $ 0.20 $ 1,102.3 $ 973.9 $ 849.8 4.11 $ 3.62 $ 3.21 $ 2.80 $ 4.04 $ 3.55 $ 3.16 $ 2.78 $ 2,692.2 1,766.3 326.1 4,784.6 $ 2,520.2 1,594.9 316.9 4,432.0 $ 2,262.0 1,419.4 292.0 3,973.4 $ 2,100.6 1,309.6 273.6 3,683.8 (a) Adjusted net earnings attributable to Allergan, Inc. Adjusted net basic earnings per share attributable to Allergan, Inc. stockholders: Continuing operations Adjusted net diluted earnings per share attributable to Allergan, Inc. stockholders: Continuing operations NET SALES BY PRODUCT LINE Specialty Pharmaceuticals: Eye Care Pharmaceuticals BOTOX®/Neuromodulator Skin Care and other Total specialty pharmaceuticals Medical Devices: Breast Aesthetics Facial Aesthetics Core medical devices Other ( b ) Total medical devices Total product net sales 377.9 477.5 855.4 3.1 858.5 $ 6,197.5 377.1 387.6 764.7 764.7 $ 5,549.3 349.3 362.7 712.0 712.0 $ 5,144.0 319.1 283.8 602.9 243.3 846.2 $ 4,819.6 287.5 258.2 545.7 218.1 763.8 $ 4,447.6 P R O D U C T S O L D B Y L O C AT I O N Domestic International 62.0% 38.0% 60.9% 39.1% 60.0% 40.0% (a) The adjusted amounts represent certain non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to GAAP financial measures, please refer to pages 18 and 19 of this Annual Report. (b) Net sales for 2012 and 2011 have been retrospectively adjusted to exclude the obesity intervention business unit, which was sold on December 2, 2013 and is classified in the financial statements as a discontinued operation. The information for 2010 and 2009 has not been adjusted and obesity intervention net sales are reflected under other medical devices. 62.6% 37.4% 65.4% 34.6% Comparison of 5-Year Cumulative Total Return* Among Allergan, Inc., the S&P 500 Index, and a Peer Group $300 $250 $200 $150 $100 $50 $0 12/31/08 12/31/09 12/31/10 12/31/11 12/31/12 12/31/13 Allergan, Inc. S&P 500 Peer Group * $100 invested on 12/31/08 in stock or index, including reinvestment of dividends. Fiscal year ending December 31. The 13 companies comprising the peer group include: Abbott Laboratories, Amgen Inc., Biogen Idec Inc., Bristol-Myers Squibb Company, Celgene Corporation, ELI Lilly and Company, Endo Health Solutions Inc., Forest Laboratories, Inc., Gilead Sciences, Inc., Johnson & Johnson, St. Jude Medical, Inc., Stryker Corporation and Valeant Pharmaceuticals International, Inc. Copyright© 2014 S&P, a division of The McGraw -Hill Companies Inc. All rights reserved. Total Sales Growth R&D Spend 1 (in millions of dollars) (in millions of dollars) 1 $ 1,034.7 $ 914.5 $ 826.3 $ 761.6 $ 674.9 $ 6,197.5 $ 5,549.3 $ 5,144.0 $ 4,819.6 $ 4,447.6 17 2% 8% 7% 8% 12% -7% 13% 8% 11% 13% 09 10 111 121 13 09 10 11 12 13 2012 and 2011 sales amounts have been retrospectively adjusted to exclude the obesity intervention business. 1 Adjusted for non-GAAP items. For a reconciliation of these non-GAAP financial measures to GAAP financial measures, please refer to pages 18 and 19 of this Annual Report. Condensed Consolidated Statements of Earnings and Reconciliation of Non-GAAP Adjustments In millions, except per share data Year Ended December 31, 2013 GAAP REVENUES Specialty pharmaceuticals product net sales Medical devices product net sales $ Product net sales Other revenues Total $ – – Adjusted $ 5,339.0 858.5 Non-GAAP Adjustments GAAP $ 4,784.6 764.7 $ – – Adjusted $ 4,784.6 764.7 6,197.5 102.9 – – 6,197.5 102.9 5,549.3 97.3 – – 5,549.3 97.3 6,300.4 – 6,300.4 5,646.6 – 5,646.6 786.8 2,423.3 1,034.7 9.3 – – – 751.2 2,193.1 977.3 90.2 – 22.3 1.5 2,046.3 1,611.0 172.6 O P E R AT I N G C O S T S A N D E X P E N S E S Cost of sales (excludes amortization of acquired intangible assets) Selling, general and administrative Research and development Amortization of acquired intangible assets Legal settlement Impairment of intangible assets and related costs Restructuring charges (reversal) 795.8 2,519.4 1,042.3 116.7 – 11.4 5.5 Operating income 1,809.3 Interest income Interest expense Gain on investments, net Other, net (9.0) (a)(b) (96.1) (b)(c)(d)(e)(f) (7.6) (e)(f) (107.4) (g) – (11.4) (h) (5.5) (i) 237.0 (0.4) (q)(r) (18.9) (r)(s)(t)(u) (62.8) (t)(u) (66.7) (g) – (22.3) (v) (1.5) (i) 750.8 2,174.2 914.5 23.5 – – – 1,783.6 6.8 (75.0) – (10.3) – 0.4 (j) – (7.4) (k)(l)(m) 6.8 (74.6) – (17.7) 6.7 (63.6) – (23.1) – 0.9 – 15.3 (78.5) (7.0) (85.5) (80.0) 16.2 Earnings from continuing operations before income taxes Provision for income taxes 1,730.8 458.3 230.0 59.8 (n) 1,960.8 518.1 1,531.0 430.3 188.8 45.2 (x) 1,719.8 475.5 Earnings from continuing operations Earnings (loss) from discontinued operations Loss on sale of discontinued operations 1,272.5 14.1 (297.9) 170.2 (14.1) (o) 297.9 (p) 1,442.7 – – 1,100.7 1.8 – 143.6 (1.8) (o) – 1,244.3 – – 454.0 – 1,442.7 3.6 1,102.5 3.7 141.8 – 1,244.3 3.7 Net earnings Net earnings attributable to noncontrolling interest 18 5,339.0 858.5 Year Ended December 31, 2012 Non-GAAP Adjustments 988.7 3.6 6.7 (62.7) – (7.8) (j) (w) (63.8) Net earnings attributable to Allergan, Inc. Net earnings per share attributable to Allergan, Inc. stockholders Basic Diluted $ 985.1 $ 454.0 $ 1,439.1 $ 1,098.8 $ 141.8 $ 1,240.6 $ $ 3.32 3.26 $ $ 1.53 1.51 $ $ 4.85 4.77 $ $ 3.64 3.58 $ $ 0.47 0.46 $ $ 4.11 4.04 Total product net sales $ 6,197.5 $ 41.1 $ 6,238.6 $ 5,549.3 $ 123.3 $ 5,672.6 The information for 2012 and 2011 in this Annual Report has been retrospectively adjusted to reflect the obesity intervention unit, which was sold on December 2, 2013, as discontinued operations. The information for 2010 and 2009 has not been adjusted. “GAAP” refers to financial information presented in accordance with generally accepted accounting principles in the United States. In this Annual Report, Allergan included historical non-GAAP financial measures, as defined in Regulation G promulgated by the U.S. Securities and Exchange Commission, with respect to the year ended December 31, 2013, as well as the corresponding periods for 2012 through 2009. Allergan believes that its presentation of historical non-GAAP financial measures provides useful supplementary information to investors regarding its operational performance because it enhances an investor’s overall understanding of the financial performance and prospects for the future of Allergan’s core business activities by providing a basis for the comparison of results of core business operations between current, past and future periods. The presentation of historical non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results as reported under GAAP. In this Annual Report, Allergan reported the non-GAAP financial measures “non-GAAP earnings attributable to Allergan, Inc.” and all of its subcomponents and related “non-GAAP basic and diluted earnings per share attributable to Allergan, Inc. stockholders.” Allergan uses non-GAAP earnings to enhance the investor’s overall understanding of the financial performance and prospects for the future of Allergan’s core business activities. Non-GAAP earnings is one of the primary indicators management uses for planning and forecasting in future periods, including trending and analyzing the core operating performance of Allergan’s business from period to period without the effect of the non-core business items indicated. Management uses non-GAAP earnings to prepare operating budgets and forecasts and to measure Allergan’s performance against those budgets and forecasts on a corporate and segment level. Allergan also uses non-GAAP earnings for evaluating management performance for compensation purposes. Despite the importance of non-GAAP earnings in analyzing Allergan’s underlying business, the budgeting and forecasting process and designing incentive compensation, non-GAAP earnings has no standardized meaning defined by GAAP. Therefore, non-GAAP earnings has limitations as an analytical tool, and should not be considered in isolation, or as a substitute for analysis of Allergan’s results as reported under GAAP. Some of these limitations are: • it does not reflect cash expenditures, or future requirements, for expenditures relating to restructurings, legal settlements, and certain acquisitions, including severance and facility transition costs associated with acquisitions; • it does not reflect asset impairment charges or gains or losses on the disposition of assets associated with restructuring and business exit activities; • it does not reflect the tax benefit or tax expense associated with the items indicated; • it does not reflect the impact on earnings of charges or income resulting from certain matters Allergan considers not to be indicative of its on-going operations; and • other companies in Allergan’s industry may calculate non-GAAP earnings differently than it does, which may limit its usefulness as a comparative measure. Allergan compensates for these limitations by using non-GAAP earnings only to supplement net earnings on a basis prepared in conformance with GAAP in order to provide a more complete understanding of the factors and trends affecting its business. Allergan strongly encourages investors to consider both net earnings and cash flows determined under GAAP as compared to non-GAAP earnings, and to perform their own analysis, as appropriate. In this Annual Report, Allergan also reported sales performance using the non-GAAP financial measure of constant currency sales. Constant currency sales represent current year reported sales adjusted (bg) (bg) for the translation effect of changes in average foreign currency exchange rates between the current year and the corresponding prior year. Allergan calculates the currency effect by comparing adjusted current year reported amounts, calculated using the monthly average foreign exchange rates for the corresponding prior year, to the actual current year reported amounts. Management refers to growth rates at constant currency so that sales results can be viewed without the impact of changing foreign currency exchange rates, thereby facilitating period-to-period comparisons of Allergan’s sales. Generally, when the dollar either strengthens or weakens against other currencies, the growth at constant currency rates will be higher or lower, respectively, than growth reported at actual exchange rates. Reporting sales performance using constant currency sales has the limitation of excluding currency effects from the comparison of sales results over various periods, even though the effect of changing foreign currency exchange rates has an actual effect on Allergan’s operating results. Investors should consider these effects in their overall analysis of Allergan’s operating results. (a) Fair market value inventory adjustment rollout of $8.9 million associated with the acquisition of SkinMedica, Inc.. (b) Expenses from changes in fair value of contingent consideration of $70.7 million included in selling, general and administrative expenses and integration and transaction costs of $19.6 million associated with business combinations, consisting of cost of sales of $0.1 million and selling, general and administrative expenses of $19.5 million. (c) Aggregate charges of $3.1 million for external costs for stockholder derivative litigation costs associated with the DOJ settlement announced in September 2010 and other legal contingency expenses. (d) Transaction costs of $1.0 million associated with a licensing agreement with Medytox, Inc.. (e) Expenses related to the realignment of various business functions of $2.8 million, consisting of selling, general and administrative expenses of $1.7 million and research and development expenses of $1.1 million. (f) Upfront licensing fee of $6.5 million included in research and development expenses associated with a license and collaboration agreement for technology that has not achieved regulatory approval and related transaction costs of $0.1 million included in selling, general and administrative expenses. (g) Amortization of certain intangible assets related to business combinations, asset acquisitions and product licenses. (h) Impairment of an intangible asset related to technology acquired in connection with the 2011 acquisition of Precision Light, Inc. (i) Net restructuring charges (reversal). (j) Interest expense associated with changes in estimated taxes related to uncertain tax positions included in prior year filings. (k) Unrealized gain of $10.4 million on the mark-to-market adjustment to derivative instruments. (l) Gain on sale of investments of $0.7 million. (m) Impairment of a non-marketable equity investment of $3.7 million. (n) Total tax effect for non-GAAP pre-tax adjustments of $(47.2) million, the estimated impact of the retroactive U.S. Research and Development tax credit for 2012 of $(15.1) million and changes in estimated income taxes related to uncertain tax positions included in prior year filings of $2.5 million. (o) Earnings (loss) from discontinued operations associated with the sale of the obesity intervention business unit. (p) Loss on the sale of discontinued operations. (q) Fair market value inventory adjustment rollout of $0.3 million associated with the purchase of a distributor’s business in Russia related to Allergan’s products. (r) Expenses from changes in fair value of contingent consideration of $5.4 million included in selling, general and administrative expenses and integration and transaction costs of $2.1 million Year Ended December 31, 2011 GAAP $ 4,432.0 712.0 $ (u) (v) (w) (x) (y) (z) (aa) (ab) (ac) (ad) (ae) (af) (ag) (ah) (ai) (aj) (ak) $ 4,432.0 712.0 GAAP $ 3,973.4 846.2 $ – – Adjusted $ 3,973.4 846.2 Non-GAAP Adjustments GAAP $ 3,683.8 763.8 $ – – Adjusted $ 3,683.8 763.8 – – 5,144.0 72.0 4,819.6 99.8 – (36.0) (ak) 4,819.6 63.8 4,447.6 56.0 – – 4,447.6 56.0 5,216.0 – 5,216.0 4,919.4 (36.0) 4,883.4 4,503.6 – 4,503.6 717.6 2,058.4 826.3 23.5 – – – 722.0 2,017.6 804.6 138.0 609.2 369.1 0.3 722.0 1,949.7 761.6 23.5 – – – 750.9 1,921.5 706.0 146.3 – – 50.9 1,590.2 258.6 1,168.0 1,426.6 928.0 7.3 (53.6) – (8.8) 7.0 (76.9) 24.6 (34.2) – 24.5 (ah) (24.6) (bc) 18.9 (bd)(be) 7.0 (52.4) – (15.3) (55.1) (79.5) 18.8 (60.7) 1,371.5 393.3 848.5 224.7 337.3 108.8 (bf) (0.4) (y) (99.9) (z)(aa)(ab)(ac)(ad) (45.2) (ab)(ae) (62.6) (g) – (7.6) (af)(ag) 0.1 (i) 1,374.6 (t) – – Adjusted Year Ended December 31, 2009 Non-GAAP Adjustments 5,144.0 72.0 718.0 2,158.3 871.5 86.1 – 7.6 (0.1) (s) Year Ended December 31, 2010 Non-GAAP Adjustments 215.6 – (67.9) (al)(am)(an)(ao)(ap) (43.0) (ao) (114.5) (g) (609.2) (aq) (369.1) (ar) (0.3) (i) (20.2) (at)(au)(av) 730.7 (91.9) (at)(av)(aw)(ax)(ay)(az)(ba) 1,829.6 (at)(au)(bb) (31.1) 674.9 (124.4) (g) 21.9 – – – – (50.9) (i) – 318.5 1,246.5 6.9 (71.8) – (0.5) – 7.3 (ah) – (9.8) (ai) 6.9 (64.5) – (10.3) 7.3 (78.7) – (16.4) – 25.1 – 7.6 (65.4) (2.5) (67.9) (87.8) 32.7 1,309.2 359.6 213.1 56.8 1,522.3 416.4 170.8 165.9 1,200.7 227.4 949.6 (11.5) – 156.3 11.5 – 1,105.9 – – 4.9 – – 973.3 – – 978.2 – – 623.8 – – 228.5 – – 852.3 – – 938.1 3.6 167.8 – 1,105.9 3.6 4.9 4.3 973.3 – 978.2 4.3 623.8 2.5 228.5 – 852.3 2.5 (aj) (o) (ah) (w) (as) 1,185.8 333.5 $ 934.5 $ 167.8 $ 1,102.3 $ 0.6 $ 973.3 $ 973.9 $ 621.3 $ 228.5 $ 849.8 $ $ 3.07 3.01 $ $ 0.55 0.54 $ $ 3.62 3.55 $ $ 0.00 0.00 $ $ 3.21 3.16 $ $ 3.21 3.16 $ $ 2.05 2.03 $ $ 0.75 0.75 $ $ 2.80 2.78 $ 5,144.0 $ (78.7) (bg) $ 5,065.3 $ 4,819.6 $ (38.7) (bg) $ 4,780.9 $ 4,447.6 $ 106.4 $ 4,554.0 associated with business combinations, consisting of cost of sales of $0.1 million and selling, general and administrative expenses of $2.0 million. Aggregate charges of $9.7 million for external costs for stockholder derivative and tax litigation associated with the DOJ settlement announced in September 2010 and other legal contingency expenses. Expenses related to the realignment of various business functions of $1.8 million, consisting of selling, general and administrative expenses of $1.5 million and research and development expenses of $0.3 million. Upfront licensing fees of $62.5 million included in research and development expenses associated with the license and collaboration agreements with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs of $0.3 million included in selling, general and administrative expenses. Impairment of an in-process research and development asset related to technology acquired in connection with the 2011 acquisition of Vicept Therapeutics, Inc. of $17.0 million and a prepaid royalty asset associated with the Sanctura® franchise of $5.3 million. Unrealized loss on the mark-to-market adjustment to derivative instruments. Total tax effect for non-GAAP pre-tax adjustments of $(52.9) million and a change in estimated income taxes related to uncertain tax positions included in prior year filings of $7.7 million. Fair market value inventory adjustment rollout associated with the purchase of a distributor’s business in South Africa related to Allergan’s products. Expenses from changes in fair value of contingent consideration of $11.9 million and integration and transaction costs of $1.9 million associated with business combinations. External costs of $3.4 million for stockholder derivative litigation costs associated with the DOJ settlement announced in September 2010. Upfront licensing fee of $45.0 million included in research and development expenses associated with a license and collaboration agreement with Molecular Partners AG for technology that has not achieved regulatory approval and related transaction costs of $0.1 million included in selling, general and administrative expenses. Upfront payment of $60.0 million and subsequent milestone payment of $20.0 million for the U.S. Food and Drug Administration acceptance of a New Drug Application filing for technology that has not achieved regulatory approval associated with a collaboration and co-promotion agreement with MAP Pharmaceuticals, Inc. and related transaction costs of $0.6 million. Costs associated with tax audit settlements for prior years’ filings of $2.0 million. Expenses related to the realignment of research and development functions of $0.2 million. Impairment of an in-process research and development asset related to a tissue reinforcement technology acquired in connection with the 2010 acquisition of Serica Technologies, Inc. of $4.3 million. Additional costs of $3.3 million for the termination of a third-party agreement primarily related to the promotion of Sanctura XR® associated with the impairment of the Sanctura® assets in the third quarter of 2010. Non-cash interest expense associated with amortization of convertible debt discount. Unrealized gain on the mark-to-market adjustment to derivative instruments of $11.1 million, gain on sale of investments of $1.9 million and impairment of a non-marketable equity investment of $3.2 million. Total tax effect for non-GAAP pre-tax adjustments. Net licensing fee of $36.0 million for a development and commercialization agreement with Bristol-Myers Squibb Company. (bg) (al) External costs of $14.4 million associated with responding to the DOJ subpoena announced in a company press release on March 3, 2008 and related stockholder derivative litigation costs associated with the DOJ settlement. (am) Expenses from changes in fair value of contingent consideration of $7.9 million and integration and transaction costs of $1.6 million associated with business combinations. (an) Distributor termination fee of $33.0 million associated with the purchase of a distributor’s business in Turkey related to Allergan’s products. (ao) Upfront licensing fee of $43.0 million included in research and development expenses associated with a license, development and commercialization agreement with Serenity Pharmaceuticals, LLC for technology that has not achieved regulatory approval and related transaction costs of $0.4 million included in selling, general and administrative expenses. (ap) Writeoff of manufacturing assets related to the abandonment of an eye care product of $10.6 million. (aq) Legal settlement costs associated with an announced resolution with the DOJ regarding Allergan’s past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX®. (ar) Aggregate charges related to the impairment of the SANCTURA® assets. (as) Total tax effect for non-GAAP pre-tax adjustments of $(226.7) million and an income tax benefit of $(0.7) million for a change in estimated income taxes related to uncertain tax positions included in prior year filings. (at) Compensation expense from stock option modifications related to the restructuring plan announced in February 2009 of $78.6 million, consisting of cost of sales of $5.0 million, selling, general and administrative expenses of $52.6 million and research and development expenses of $21.0 million. (au) Rollout of retention termination benefits and accelerated depreciation costs capitalized in inventory of $14.4 million included in cost of sales and one-time termination benefits of $0.1 million included in research and development expenses related to the phased closure of the Arklow, Ireland breast implant manufacturing facility. (av) Fair market value inventory adjustment rollout of $0.8 million included in cost of sales and transaction costs of $0.4 million included in selling, general and administrative expenses related to the creation of Samil Allergan Ophthalmic Joint Venture Company. (aw) External costs of $32.2 million associated with responding to the DOJ subpoena. (ax) Asset impairments and accelerated depreciation costs related to the 2009 restructuring plan of $2.3 million. (ay) Integration and transition costs related to the acquisition of Groupe Cornéal Laboratoires of $0.4 million. (az) Contribution to The Allergan Foundation of $18.0 million. (ba) Gain on settlement of a manufacturing and distribution agreement of $14.0 million related to an eye care pharmaceuticals product. (bb) Upfront payment of $10.0 million for a license and development agreement with Pieris AG for technology that has not achieved regulatory approval. (bc) Net gain on sale of investments. (bd) Unrealized loss on the mark-to-market adjustment to derivative instruments of $13.6 million. (be) Loss on extinguishment of convertible debt of $5.3 million. (bf) Total tax effect for non-GAAP pre-tax adjustments of $(106.2) million, a net expense of $4.1 million for a change in estimated income taxes related to pre-acquisition periods associated with business combinations and uncertain tax positions included in prior year filings and an income tax benefit of $(6.7) million related to foreign research and development tax credits. (bg) The adjustment to measure sales using constant currency. 19 Board of Directors David E.I. Pyott, 60, Chairman of the Board and Chief Executive Officer Elected to the Board and joined Allergan in 1998. Mr. Pyott has been Chief Executive Officer of Allergan since January 1998 and in 2001 became Chairman of the Board. Mr. Pyott also served as President of Allergan from January 1998 until February 2006, and again from March 2011 until June 2013. Previously, Mr. Pyott served as head of the Nutrition Division and a member of the Executive Committee of Novartis AG. Mr. Pyott is a director of Edwards Lifesciences Corporation as well as Avery Dennison Corporation, where he also serves as the lead independent director. Mr. Pyott serves on the board and Executive Committee of the California Healthcare Institute; is a member of the Directors’ Board of The Paul Merage School of Business at the University of California, Irvine (UCI); and serves on the board and Executive Committee of the Biotechnology Industry Organization. Mr. Pyott is a member of the board of the Pan-American Ophthalmological Foundation and is a member of the Advisory Board for the Foundation of The American Academy of Ophthalmology. Mr. Pyott also serves as a Vice Chairman of the Board of Trustees of Chapman University. Deborah Dunsire, M.D., 51 Dr. Dunsire was appointed to the Board in 2006, and serves on our Audit and Finance Committee and our Science and Technology Committee. Dr. Dunsire has served as President and Chief Executive Officer of EnVivo Pharmaceuticals since July 2013. Prior to joining EnVivo, she served as President and Chief Executive officer of Millennium Pharmaceuticals, Inc., The Takeda Oncology Company, from July 2005 to July 2013. Dr. Dunsire served on the board of directors of Takeda Pharmaceutical Company Limited in Japan. Prior to joining Millennium, Dr. Dunsire led the Novartis U.S. Oncology Business, playing a critical role in the broad development and successful launch of a number of products. Dr. Dunsire was also responsible for managing the merger and significant growth of the combined Sandoz Pharmaceuticals and Ciba-Geigy oncology businesses. Dr. Dunsire served on the U.S. Pharmaceutical Executive Committee at Novartis. Dr. Dunsire is a former board member of the Biotechnology Industry Organization. Dr. Dunsire was the 2001 recipient of the American Cancer Society’s Excalibur Award and is the 2009 recipient of The Healthcare Businesswomen’s Association’s “Woman of the Year.” David E.I. Pyott Deborah Dunsire Michael R. Gallagher, 68 Mr. Gallagher was elected to the Board in 1998, and serves as our Lead Independent Director. He is the Chair of our Corporate Governance and Compliance Committee and the Chair of our Organization and Compensation Committee. In 2004, Mr. Gallagher retired as Chief Executive Officer and as a Director of Playtex Products, Inc. Prior to joining Playtex in 1995, Mr. Gallagher was Chief Executive Officer of North America for Reckitt & Colman plc; President and Chief Executive Officer of Eastman Kodak’s subsidiary, L&F Products; President of the Lehn & Fink Consumer Products Division at Sterling Drug, General Manager of the Household Products Division of the Clorox Company, and Brand Manager of The Procter & Gamble Company. Mr. Gallagher is a member and past Chairman of the Board of Advisors of the Haas School of Business, University of California, Berkeley. 20 Trevor M. Jones, Ph.D., 71 Prof. Jones was appointed to the Board in 2004, and is the Chair of our Science and Technology Committee and serves on our Corporate Governance and Compliance Committee. From 1994 to 2004, Prof. Jones was the Director General of the Association of the British Pharmaceutical Industry. From 1987 to 1994, Prof. Jones was a main board director at Wellcome plc. Prof. Jones received his bachelor of pharmacy degree and Ph.D. from the University of London. Prof. Jones has also gained an honorary doctorate from the University of Athens as well as honorary doctorates in science from the Universities of Strathclyde, Nottingham, Bath and Bradford in the United Kingdom. Furthermore, Prof. Jones was recognized in the Queen’s Honors List and holds the title of Commander of the British Empire. Prof. Jones is also a Fellow of the Royal Society of Chemistry, a Fellow of the Royal Society of Medicine, a Fellow of The Royal Pharmaceutical Society, an honorary Fellow of the Royal College of Physicians and of its Faculty of Pharmaceutical Medicine, and an honorary Fellow of the British Pharmacological Society. Prof. Jones is a board member of Arthurian Life Sciences Ltd., Simbec Research Ltd., Synexus Ltd., and Verona Pharma plc. Prof. Jones is also a founder of the Geneva-based public-private partnership, Medicines for Malaria Venture and the UK Stem Cell Foundation. Louis J. Lavigne, Jr., 65 Mr. Lavigne was appointed to the Board in 2005, and serves on our Audit and Finance Committee and our Science and Technology Committee. Mr. Lavigne is the Managing Director of Lavrite, LLC, a management consulting firm in the areas of corporate finance, accounting, management and strategy since 2005. Mr. Lavigne was Executive Vice President and Chief Financial Officer of Genentech, Inc. from March 1997 through his retirement in March 2005, leading the company through significant growth while overseeing the financial, corporate relations and information technology groups. Mr. Lavigne joined Genentech in July 1982, was named controller in 1983, and, in that position, built Genentech’s operating financial functions. In 1986, Mr. Lavigne was promoted to Vice President and assumed the position of Chief Financial Officer in September of 1988. Mr. Lavigne was named Senior Vice President in 1994 and was promoted to Executive Vice President in 1997. Prior to joining Genentech, Mr. Lavigne held various financial management positions with Pennwalt Corporation, a pharmaceutical and chemical company. Mr. Lavigne serves on the board of Accuray Incorporated, Depomed, Inc., DocuSign, Inc., Novocure Limited and SafeNet Inc. Mr. Lavigne is a faculty member of the Babson College Executive Education’s Bio-Pharma: Mastering the Business of Science program. Mr. Lavigne is a member of the West Audit Committee Chair Network. Mr. Lavigne is a board member of Children’s Hospital Oakland, its Foundation and the Children’s Enterprise Council with UCSF. Mr. Lavigne is also a trustee of Babson College and Babson Global. Mr. Lavigne is a former trustee of the California Institute of Technology and the Seven Hills School. Michael R. Gallagher Trevor M. Jones Louis J. Lavigne, Jr. Peter J. McDonnell, M.D., 55 Dr. McDonnell was appointed to the Board in 2013, and serves on our Corporate Governance and Compliance Committee and our Science and Technology Committee. Dr. McDonnell is the Director and William Holland Wilmer Professor of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine since 2003. Dr. McDonnell also serves as the Chief Medical Editor of Ophthalmology Times since 2004, and has served on the editorial boards of numerous ophthalmology journals. Dr. McDonnell also served as the Assistant Chief of Service at the Wilmer Institute from 1987 to 1988. He served as a consultant to the United States Department of Health and Human Services in 1996. Dr. McDonnell served as a full-time faculty at the University of Southern California from 1988 until 1999, where he advanced to the rank of professor in 1994. Dr. McDonnell is an international leader in corneal transplantation, laser refractive surgery and the treatment of dry eye. Dr. McDonnell’s research interests include the causes and correction of refractive error, corneal wound healing and microbial keratitis. In 1999, Dr. McDonnell was named the Irving H. Leopold Professor and Chair of the Department of Ophthalmology at the University of California, Irvine (UCI). He is the recipient of research grants from the National Eye Institute, Research to Prevent Blindness, and other funding agencies. He has published over 250 scientific articles and holds four patents. The American Academy of Ophthalmology honored him with the Honor Award in 1991 and the Senior Achievement Award in 2001. In 2003, he received the Alcon Research Institute Award. Dr. McDonnell has served on the editorial boards of six ophthalmology journals. Dr. McDonnell is a member of many professional ophthalmology and medical societies. Peter J. McDonnell Timothy D. Proctor, 64 Mr. Proctor was elected to the Board in 2013, and serves on the Organization and Compensation Committee and the Audit and Finance Committee. Mr. Proctor served as General Counsel at Diageo PLC since 2000 until July 2013. Prior to joining Diageo, Mr. Proctor served as the Director, Worldwide Human Resources, of Glaxo Wellcome, plc (now GlaxoSmithKline plc), a British multinational pharmaceutical company, from 1998 to 1999. From 1993 to 1998, Mr. Proctor held various roles with the U.S. operating subsidiary of Glaxo Wellcome, plc., including Senior Vice President, Human Resources, General Counsel and Secretary. Prior to that, Mr. Proctor served in senior legal roles at Merck & Co., a publicly-traded pharmaceutical company, from 1980 to 1993. Mr. Proctor is a well-respected leader in the area of international law, with more than 35 years of domestic and international corporate legal experience. Russell T. Ray, 66 Mr. Ray was appointed to the Board in 2003, and is the Chair of our Audit and Finance Committee and serves on our Organization and Compensation Committee. Mr. Ray is a Special Advisor to HLM Venture Partners, a private equity firm that provides venture capital to health care information technology, health care services and medical technology companies. Prior to joining HLM Venture Partners in 2003, Mr. Ray was Founder, Managing Director and President of Chesapeake Strategic Advisors from April 2002 to August 2003 and was the Global Co-Head of the Credit Suisse First Boston Health Care Investment Banking Group, where he focused on providing strategic and financial advice to life sciences, health care services and medical device companies from 1999 to 2002. Prior to joining Credit Suisse First Boston in 1999, Mr. Ray spent 12 years at Deutsche Bank and its predecessor entities BT Alex.Brown and Alex.Brown & Sons, Inc. as Global Head of Health Care Investment Banking. Mr. Ray is a director of Prism Education Group, Inc. and SWP Media, Inc. Mr. Ray served as a director of InfoMedics, Inc. from December 2009 until December 2012 when the company was acquired. Mr. Ray is also a member of the Midwest Peregrine Society. Timothy D. Proctor Russell T. Ray Henri A. Termeer, 68 Mr. Termeer was appointed to the Board in 2014, and serves on our Corporate Governance and Compliance Committee and our Organization and Compensation Committee. Mr. Termeer served as President and a director of Genzyme Corporation, a leading global public biotechnology company, beginning October 1983, as Chief Executive Officer beginning 1985 and as Chairman of the Board beginning May 1988. Mr. Termeer resigned from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. In 2008, he was appointed to Massachusetts Governor Deval Patrick’s Council of Economic Advisors. Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer is active in the areas of humanitarian assistance, policy issues, and innovation in providing access to health care. Mr. Termeer is a director of Massachusetts General Hospital, a board member of Partners HealthCare and a member of the board of fellows of Harvard Medical School. Mr. Termeer is also a member of the board of the Massachusetts Institute of Technology and serves on its Executive Committee, a board member of the Biotechnology Industry Organization, the Life Sciences Foundation, WGBH and Boston Ballet. He is chairman emeritus of the New England Healthcare Institute, a nonprofit, applied research health policy organization he was instrumental in founding. Mr. Termeer has been recognized by many highly regarded organizations for his contributions to the healthcare field and global business. In 2010, he was inducted into the Academy of Distinguished Entrepreneurs, which was established by Babson College to recognize the economic and social contributions of business pioneers. Mr. Termeer received the Pharmaceuticals and Biotechnology Lifetime Achievement Award from Frost and Sullivan in 2009, and was selected by Ernst & Young for its Master Entrepreneur Award in 2007 for the role he has played in guiding the overall development of the biotech industry. Mr. Termeer has also been inducted as a Fellow in the American Academy of Arts and Sciences and was elected in 2005 to Honorary Fellowship at the British Royal College of Physicians. Henri A. Termeer 21 Executive Committee David E.I. Pyott, 60, Chairman of the Board and Chief Executive Officer Mr. Pyott joined Allergan in January 1998 as President and Chief Executive Officer (CEO) and now serves as Chairman of the Board (since 2001), and CEO. Previously, he was head of the Nutrition Division and a member of the Executive Committee of Novartis AG from 1995 through 1997. Mr. Pyott has about 30 years of international experience in nutrition and health care and has worked in Austria, Germany, the Netherlands, Spain, Switzerland, Malaysia, Singapore, and the United Kingdom. Mr. Pyott holds a diploma in European and International Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh, and a Master of Business Administration degree from the London Business School. He also has been honored in the Queen’s Birthday Honors List in 2006 and holds the title of Commander of the British Empire, and was awarded the University of David E.I. Pyott California, Irvine Medal in 2010. Raymond H. Diradoorian, 56, Executive Vice President, Global Technical Operations Mr. Diradoorian has been Executive Vice President, Global Technical Operations since February 2006. From April 2005 to February 2006, Mr. Diradoorian served as Senior Vice President, Global Technical Operations. Since February 2001, Mr. Diradoorian served as Vice President, Global Engineering and Technology. Mr. Diradoorian joined Allergan in July 1981. Prior to joining Allergan, Mr. Diradoorian held positions at American Hospital Supply and with the Los Angeles Dodgers baseball team. Mr. Diradoorian received a Bachelor of Science degree in Biological Sciences from the University of California, Irvine and a Master of Science degree Raymond H. Diradoorian in Technology Management from Pepperdine University. Jeffrey L. Edwards, 53, Executive Vice President, Finance and Business Development, Chief Financial Officer Mr. Edwards has been Executive Vice President, Finance and Business Development, Chief Financial Officer, since September 2005. Mr. Edwards joined Allergan in 1993. From March 2003 to September 2005, Mr. Edwards served as Corporate Vice President, Corporate Development and previously served as Senior Vice President, Treasury, Tax and Investor Relations. Prior to joining Allergan, Mr. Edwards was with Banque Paribas and Security Pacific National Bank, where he held various senior-level positions in the credit and business development functions. Mr. Edwards completed the Advanced Management Program at the Harvard Business School and received a Bachelor of Arts degree in Sociology from Muhlenberg College. Jeffrey L. Edwards Julian S. Gangolli, 56, Corporate Vice President and President, North America Mr. Gangolli has been Corporate Vice President and President, North America since January 2004. Mr. Gangolli served as Senior 22 Vice President, U.S. Eye Care from July 1998 to January 2004. Prior to joining Allergan, Mr. Gangolli served as Vice President, Sales and Marketing of VIVUS, Inc., a publicly-traded biopharmaceutical company, from 1994 to 1998, where he was responsible for facilitating the successful transition of the company from a research and development start-up into a niche pharmaceutical company. Prior to that, Mr. Gangolli served in a number of increasingly senior marketing roles in the UK, Global Strategic Marketing and in the U.S. for Syntex Pharmaceuticals, Inc., a multinational pharmaceutical company. Mr. Gangolli began his career in pharmaceutical sales and marketing with Ortho-Cilag Pharmaceuticals, Ltd. a UK subsidiary of Johnson & Johnson. Mr. Gangolli received a BSc Julian S. Gangolli (Honors) in Applied Chemistry and Business Studies from Kingston Polytechnic in England. Douglas S. Ingram, Esq., 51, President Mr. Ingram was appointed President of Allergan on July 1st, 2013. Prior to assuming his current role, Mr. Ingram served as Executive Vice President and President, Europe, Africa and Middle East from August 2010 to June 2013, and Executive Vice President, Chief Administrative Officer, and Secretary from October 2006 to July 2010 where he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments. Mr. Ingram also served as General Counsel from January 2001 to June 2009 and as Secretary and Chief Ethics Officer from July 2001 to July 2010. During that time, he served as Executive Vice President from October 2003 to October 2006, as Corporate Vice President from July 2001 to October 2003 and as Senior Vice President from January 2001 to July 2001. Prior to that, Mr. Ingram was Associate General Counsel and Assistant Secretary from 1998 and joined Allergan in 1996 as Senior Attorney and Chief Litigation Counsel. Prior to joining Allergan, Mr. Ingram was an attorney at Gibson, Dunn & Crutcher LLP from 1988 to 1996. Mr. Ingram received his Juris Doctorate from the University of Arizona in 1988, graduating summa cum laude and Order of the Coif. Douglas S. Ingram, Esq. Arnold A. Pinkston, 55, Executive Vice President, General Counsel and Assistant Secretary Mr. Pinkston joined Allergan as Executive Vice President, General Counsel and Assistant Secretary in October 2011 with over 25 years of experience managing legal affairs. Prior to joining Allergan, Mr. Pinkston served as the Senior Vice President, General Counsel and Secretary of Beckman Coulter, Inc. from 2005 through the company’s sale to Danaher Corporation in June 2011. While at Beckman Coulter, Mr. Pinkston was responsible for all aspects of the company’s global legal affairs as well as the company’s compliance program, corporate social responsibility program, internal audit department and knowledge resources. Prior to joining Beckman Coulter, Mr. Pinkston held various positions at Eli Lilly and Company from 1999 through 2005, including serving as deputy general counsel responsible for the legal affairs of Lilly USA. Mr. Pinkston served as general counsel of PCS Health Arnold A. Pinkston Systems from 1994 to 1999 after working for McKesson Corporation and beginning his legal career as an attorney with Orrick, Herrington & Sutcliffe. Mr. Pinkston received a Bachelor’s Degree in Geophysics from Yale College and a Juris Doctor degree from Yale Law School. Scott D. Sherman, 48, Executive Vice President, Human Resources Mr. Sherman joined Allergan as Executive Vice President, Human Resources in September 2010 with more than 15 years of human resources leadership experience. Prior to joining Allergan, Mr. Sherman worked at Medtronic, Inc. from August 1995 to September 2010 in roles of increasing complexity and responsibility. Most recently, Mr. Sherman served as Medtronic’s Vice President, Global Total Rewards and Human Resources Operations, where he was responsible for global executive compensation, base pay, short-term and long-term incentive programs, as well as health, retirement, life, disability, wealth accumulation and wellness. Mr. Sherman held a series of other positions at Medtronic including Vice President, International Human Resources; Vice President, Human Resources - Europe, Emerging Markets and Canada; and Vice-President, Human Resources Diabetes. Prior to joining Scott D. Sherman Medtronic, Mr. Sherman held various positions in the Human Resources and Sales organizations at Exxon Corporation from 1990 to 1995. Mr. Sherman holds a Master’s Degree in Industrial and Labor Relations from Cornell University and a Bachelor’s Degree in International Affairs from The George Washington University. Scott M. Whitcup, M.D., 54, Executive Vice President, Research and Development, Chief Scientific Officer Dr. Whitcup has been Executive Vice President, Research and Development since July 2004 and in April 2009 became Chief Scientific Officer. Dr. Whitcup joined Allergan in 2000. Prior to joining Allergan, Dr. Whitcup served as the Clinical Director of the National Eye Institute at the National Institutes of Health. As Clinical Director, Dr. Whitcup’s leadership was vital in building the clinical 23 research program and developing new therapies for ophthalmic diseases. Dr. Whitcup graduated from Cornell University and Cornell University Medical College. He completed residency training in internal medicine at the University of California, Los Angeles and in ophthalmology at Harvard University, as well as fellowship training in uveitis and ocular immunology at the National Institutes of Health. Dr. Whitcup is a faculty member at the Jules Stein Eye Institute/David Geffen School of Medicine at the University of California, Los Angeles. Other Executive Officer James F. Barlow (Not Pictured) Senior Vice President, Corporate Controller (Principal Accounting Officer) Scott M. Whitcup Corporate Overview and Stockholders’ Information Corporate Headquarters Market Prices of Common Stock and Dividends Allergan, Inc. The following table shows the quarterly price range of the common stock 2525 Dupont Drive and the cash dividends declared per share during the period listed. Irvine, CA 92612-1599 (714) 246-4500 Calendar Quarter E-mail: corpinfo@allergan.com Internet: www.allergan.com Transfer Agent, Registrar and Dividend Disbursing Agent Wells Fargo Shareowner Services P.O. Box 64874 St. Paul, MN 55164-0874 (800) 468-9716 2013 Low First 2012 High Div Low High Div $92.19 $112.30 $0.05 $84.30 $96.39 $0.05 Second 81.33 116.45 0.05 87.69 97.09 0.05 Third 82.56 93.25 0.05 81.28 95.75 0.05 Fourth 88.34 111.45 0.05 86.51 95.44 0.05 Allergan common stock is listed on the New York Stock Exchange and is traded under the symbol “AGN.” The approximate number of stockholders of record was 4,420 as of February 14, 2014. Internet: https://www.shareowneronline.com Annual Meeting of Stockholders The Annual Meeting of Stockholders of Allergan, Inc. will be held at Allergan’s corporate headquarters, 2525 Dupont Drive, Irvine, CA, 92612, Trademarks ® and ™ Marks owned by Allergan, Inc. JUVÉDERM is a registered trademark of Allergan Industrie SAS. on May 6, 2014, at 10:00 a.m. Pacific Time. 24 For inquiries related to the Annual Meeting of Stockholders, please contact: DARPin is a registered trademark of Molecular Partners AG. Matthew J. Maletta Allergan, for the year ending December 31, 2013, continued its proud Allergan, Inc. tradition of placement in the top quartile for environmental health and P.O. Box 19534 safety performance within its pharmaceutical company peer group. Irvine, CA 92623-9534 More information on its sustainability performance worldwide can be Phone: (714) 246-5185 found by visiting the “Responsibility” section on Allergan’s corporate Fax: (714) 246-4774 Web site at www.allergan.com, and selecting the “Environmental Health Form 10-K and Safety Information” page. A copy of Allergan, Inc.’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, is available through our Web site at www.allergan.com or without charge by contacting: Investor Relations James M. Hindman Allergan, Inc. P.O. Box 19534 Irvine, CA 92623-9534 Phone: (714) 246-4636 Fax: (714) 246-4162 E-mail: corpinfo@allergan.com Dividend Reinvestment and Stock Purchase Plan The plan allows Allergan stockholders to reinvest their dividends or invest cash in Allergan stock without brokerage commissions or service charges. If you are interested in joining the plan or would like more information, you may request a prospectus from the below address or access the information online at: https://www.shareowneronline.com: Wells Fargo Shareowner Services Dividend Reinvestment Plan Allergan, Inc. P.O. Box 64856 St. Paul, MN 55164-0856 Photography: Eric Myer | www.ericmyer.com (executive portraits) Alain McLaughlin | www.amphotosf.com (Mr. Lavigne executive photo) Charlotte Raymond | www.charlotteraymondphotography.com (emerging markets photo) Allergan’s global values customer focus | impact | people + passion | collaboration | innovation | integrity 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623-9534 (714) 246-4500 www.allergan.com NYSE: AGN